The Patient-Centered Outcomes Research Institute (PCORI) will approach biosimilar research the way it does research on anything else, but there is the added element of finding the right timing, said Joe V. Selby, MD, MPH, executive director of PCORI.
The Patient-Centered Outcomes Research Institute (PCORI) will approach biosimilar research the way it does research on anything else, but there is the added element of finding the right timing, said Joe V. Selby, MD, MPH, executive director of PCORI.
Transcript (slightly modified)
How does PCORI plan to address biosimilar research now that the FDA has approved the first one in the United States?
We'll approach research on biosimilars like we approach on research on everything else. We are beginning to hear from stakeholders that we should be interested in biosimilars. We're prepared to beleive they might be right, but we're going to want to get multiple stakeholders together and then prioritize the question. And sometimes the most challenging work, from anyone's perspective and particularly from the perspective of multiple stakeholders at the same time: what is the right question? What's the question that will change practice? What's the question that the answer will endure?
It's a lot of fun. People enjoy doing it. It makes a lot of sense that you would try to get patients, payers, manufacturers, and clinicians in the same room, to discuss these topics. But I will say, and all of them will say too, that's hard work—identifying the exact right questions. But in biosimilars, it will go through the process of being reviewed, we will prepare a topic brief on the question, we'll go to the advisory panels.
I think with biosimilars one of the questions is: when do we start? We like to be there early. But you could get there too early in this country. So we need to get the questions right. See if multiple stakeholders agree that this is high-priority research for PCORI and determine the best time to start.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More